Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Lancet Diabetes Stories

2014-04-08 09:58:09

Gastric banding can play a vital role in the treatment of type 2 diabetes in people who are overweight and not obese, according to new research. The Monash University study, led by Emeritus Professor Paul O’Brien from Monash University’s Centre for Obesity Research and Education (CORE) and Dr John Wentworth from CORE and the Walter and Eliza Hall Institute, has determined that weight loss surgery (gastric banding) for overweight people with diabetes had a profound impact on the...

2013-09-23 10:22:14

Encouraging results from the T1DAL study (Targeting effector memory T cells with alefacept in new onset type 1 diabetes), led by Mark R. Rigby M.D., Ph.D. from Indiana University and Riley Hospital for Children in Indianapolis and sponsored by the Immune Tolerance Network (ITN) with additional support from JDRF, are published today in The Lancet Diabetes & Endocrinology. Alefacept, an engineered fusion protein targeting a surface molecule, CD2, found on T-lymphocytes, was the first...

2013-08-20 10:36:26

Researchers at Kaiser Permanente and the University Medical Centre Utrecht in the Netherlands have created the first risk score that predicts the 10-year individualized dementia risk for patients with type 2 diabetes, as reported in the inaugural issue of Lancet Diabetes & Endocrinology. The researchers developed and validated the Diabetes-Specific Dementia Risk Score by examining data from nearly 30,000 patients with type 2 diabetes aged 60 and older over a 10-year period. They found...